MedPath

TAK-754

Generic Name
TAK-754
Drug Type
Biotech

Overview

TAK-754 is an adeno-associated virus serotype 8 vector (AAV8) expressing B domain deleted codon optimized factor VIII. Developed by Takeda, it is being investigated for the treatment of hemophilia A.

Background

TAK-754 is an adeno-associated virus serotype 8 vector (AAV8) expressing B domain deleted codon optimized factor VIII. Developed by Takeda, it is being investigated for the treatment of hemophilia A.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Phase 1
Completed
Posted: 2017/12/12
Sponsor:
Baxalta now part of ...

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath